It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.

With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.

This program offers expert insights into current recommendations of care for patients with breast cancer and includes the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Individualized patient care is highly important in acute myeloid leukemia (AML) therapy to ensure the most effective treatment regimens can be selected for appropriate patients.

Education on this topic can provide useful information on how to find the necessary information required to accurately recommend the best therapy option.

T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.

Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.

Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.

Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.